Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DRAGOS G ZANCHI

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1922068550
CMS profile
223563
Location
BRANDON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,949.34

140 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,949.34 140

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DRAGOS G ZANCHI

NPI 1922068550 · CMS profile ID 223563

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

BRANDON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922068550?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DRAGOS G ZANCHI, NPI 1922068550, CMS profile ID 223563. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922068550?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DRAGOS G ZANCHI, NPI 1922068550, CMS profile ID 223563. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922068550?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DRAGOS G ZANCHI, NPI 1922068550, CMS profile ID 223563, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 140 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1922068550?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

140 matching records · $3,949.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 140 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 140.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Philips North America LLC $18.4109/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232593207 CMS
Inspire Medical Systems, Inc. $90.4009/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251521914 CMS
Electromed, Inc. $13.4309/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224581004 CMS
GENZYME CORPORATION $42.8909/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233412122 CMS
Regeneron Pharmaceuticals, Inc. $42.8009/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213245079 CMS
AstraZeneca Pharmaceuticals LP $24.6309/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206753642 CMS
Pulmonx Corporation $19.1608/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1199550454 CMS
Grifols USA, LLC $16.3208/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249575563 CMS
United Therapeutics Corporation $27.6308/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242531714 CMS
AstraZeneca Pharmaceuticals LP $19.4408/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206504016 CMS
GlaxoSmithKline, LLC. $13.5108/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190374821 CMS
ANI Pharmaceuticals, Inc. $33.5908/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248615130 CMS
GlaxoSmithKline, LLC. $20.7508/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191677879 CMS
Grifols USA, LLC $33.7008/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249575555 CMS
Amgen Inc. $23.7808/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228380834 CMS
Takeda Pharmaceuticals U.S.A., Inc. $31.4908/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223926505 CMS
GENZYME CORPORATION $13.6708/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233412098 CMS
GlaxoSmithKline, LLC. $18.7208/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190902307 CMS
AstraZeneca Pharmaceuticals LP $23.0908/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207169263 CMS
GlaxoSmithKline, LLC. $15.1308/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190825968 CMS
Baxter Healthcare $14.0408/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181545148 CMS
GENZYME CORPORATION $27.9508/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233412102 CMS
GENZYME CORPORATION $78.7308/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233412108 CMS
Lilly USA, LLC $22.8108/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186631017 CMS
Mallinckrodt Hospital Products Inc. $20.3008/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212009501 CMS
GlaxoSmithKline, LLC. $22.8508/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190576792 CMS
GlaxoSmithKline, LLC. $23.9608/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190801530 CMS
Grifols USA, LLC $24.7207/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249575557 CMS
Lilly USA, LLC $17.9407/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186631015 CMS
Regeneron Pharmaceuticals, Inc. $99.3207/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213245077 CMS
GlaxoSmithKline, LLC. $29.7807/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191030923 CMS
AstraZeneca Pharmaceuticals LP $16.5907/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206377717 CMS
Insmed, Inc. $30.9707/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186311768 CMS
Mallinckrodt Hospital Products Inc. $28.5807/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212009499 CMS
AstraZeneca Pharmaceuticals LP $18.3107/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206577658 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.4107/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222852700 CMS
GlaxoSmithKline, LLC. $31.1307/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190762932 CMS
GlaxoSmithKline, LLC. $25.7307/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190421845 CMS
INTUITIVE SURGICAL, INC. $11.4007/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236623368 CMS
GlaxoSmithKline, LLC. $23.3506/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191032592 CMS
Amgen Inc. $21.7506/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228380826 CMS
Grifols USA, LLC $31.1406/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249575561 CMS
Electromed, Inc. $16.3106/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224581011 CMS
GlaxoSmithKline, LLC. $12.8806/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191355663 CMS
Verona Pharma, Inc. $21.7906/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233799616 CMS
GlaxoSmithKline, LLC. $18.5206/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191696921 CMS
GlaxoSmithKline, LLC. $11.4906/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190521934 CMS
GlaxoSmithKline, LLC. $27.3405/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190501795 CMS
Grifols USA, LLC $33.8605/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249575559 CMS
SomnoMed Inc. $132.5605/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181914914 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,295.79 141
PY2020 $4,500.84 104
PY2021 $9,732.01 155
PY2022 $9,169.61 140
PY2023 $12,882.44 141
PY2024 $2,860.71 127
PY2025 $3,949.34 140

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $361,937.65 219
PY2024 Principal investigator $303,084.68 159
PY2023 Principal investigator $137,801.84 58
PY2022 Principal investigator $104,462.65 11
PY2021 Principal investigator $16,849.89 3
PY2020 Principal investigator $39,072.47 3
PY2019 Principal investigator $16,886.83 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

219 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $4,339.00 12/23/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617795
Principal investigator 1 Alkermes, Inc. $6,027.00 12/23/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621262
Principal investigator 1 Alkermes, Inc. $9,051.00 12/23/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624120
Principal investigator 1 Alkermes, Inc. $70.00 12/23/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625702
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $704.70 12/17/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223289828
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $202.00 12/17/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223289830
Principal investigator 1 Alkermes, Inc. $53.00 12/08/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615037
Principal investigator 1 Alkermes, Inc. $107.40 12/08/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620792
Principal investigator 1 Alkermes, Inc. $131.60 12/08/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621855
Principal investigator 1 Alkermes, Inc. $172.25 12/08/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625175
Principal investigator 1 Alkermes, Inc. $105.00 12/01/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622747
Principal investigator 1 Alkermes, Inc. $70.00 12/01/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625213
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762072
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762074
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762076
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 12/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762080
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15.00 12/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220815121
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $93.50 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740918
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.42 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740920
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.20 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740922
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.31 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740924
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $46.87 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740926
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12.83 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740928
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.72 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740930
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $118.70 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740932
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $221.38 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740934
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8.12 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740936
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.27 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740938
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $17.80 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740940
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $15.05 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740942
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740944
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $37.40 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740946
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $45.61 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740948
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $11.00 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740950
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.60 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740952
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.96 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740954
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.84 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740956
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.33 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740958
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $30.10 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740960
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740962
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $119.28 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740964
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.40 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740966
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740968
Principal investigator 1 Alkermes, Inc. $3,000.00 11/10/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624122
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762064
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762066
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762068
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 11/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762070
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15.00 11/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220815119
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,825.87 10/29/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223287733
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,667.53 10/29/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223287735
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,902.32 10/29/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223287737
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 10/27/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762082
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762084
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 10/27/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762086
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 10/27/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762088
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 10/27/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762090
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 10/27/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762092
Principal investigator 1 AstraZeneca Pharmaceuticals LP $742.20 10/17/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH, LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185552827
Principal investigator 1 Alkermes, Inc. $11,000.00 10/08/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621054
Principal investigator 1 Alkermes, Inc. $1,500.00 10/08/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624374
Principal investigator 1 Alkermes, Inc. $2,555.00 10/08/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625001
Principal investigator 1 Alkermes, Inc. $600.00 10/08/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626722
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,852.92 10/08/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223286525
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 10/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762052
Principal investigator 1 Boehringer Ingelheim International GmbH $436.57 10/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762054
Principal investigator 1 Boehringer Ingelheim International GmbH $799.00 10/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762056
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762058
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 10/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762060
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 10/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762062
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 10/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762078
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15.00 10/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220815117
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 09/24/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220770737
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 09/24/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220770739
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 09/24/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220770741
Principal investigator 1 Boehringer Ingelheim International GmbH $131.10 09/24/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220770743
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220770745
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220770747
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220770749
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 09/24/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220770751
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 09/24/2025 Non-covered Recipient Entity
Meris Clinical Research
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220770753
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614713
Principal investigator 1 Alkermes, Inc. $131.60 09/03/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619555
Principal investigator 1 Alkermes, Inc. $172.25 09/03/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624426
Principal investigator 1 Alkermes, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626122
Principal investigator 1 Alkermes, Inc. $51.75 09/03/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626176
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 09/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762044
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 09/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762046
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 09/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762048
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 09/01/2025 Non-covered Recipient Entity
Meris Clinical Research
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220762050
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $139.05 08/22/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223284533
Principal investigator 1 Alkermes, Inc. $200.00 08/20/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620225
Principal investigator 1 Alkermes, Inc. $50.00 08/20/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622367
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,349.31 08/20/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740902
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $371.25 08/20/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223284415
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $233.55 08/20/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223284417
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $125.00 08/20/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223284419
Principal investigator 1 Alkermes, Inc. $70.00 08/14/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623704
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $30,709.49 08/06/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223283883
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,513.00 08/01/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223283469
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 08/01/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223283471
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $155.45 07/11/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223282570
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,000.00 07/09/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740904
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 07/09/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740906
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,600.00 07/09/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740908
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,300.00 07/09/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740910
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.00 07/09/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740912
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,600.00 07/09/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740914
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 07/09/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740916
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613539
Principal investigator 1 Alkermes, Inc. $5.95 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614274
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615767
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616199
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617091
Principal investigator 1 Alkermes, Inc. $25.68 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617475
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617655
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617659
Principal investigator 1 Alkermes, Inc. $1.09 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618137
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618171
Principal investigator 1 Alkermes, Inc. $179.90 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618375
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618385
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619021
Principal investigator 1 Alkermes, Inc. $192.75 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619579
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621066
Principal investigator 1 Alkermes, Inc. $200.20 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621540
Principal investigator 1 Alkermes, Inc. $28.14 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621704
Principal investigator 1 Alkermes, Inc. $27.82 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622843
Principal investigator 1 Alkermes, Inc. $7.70 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623580
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624822
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624897
Principal investigator 1 Alkermes, Inc. $33.32 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625049
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625099
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626526
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 06/13/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740886
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 06/13/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740890
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 06/13/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740892
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,000.00 06/13/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740894
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,600.00 06/13/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740896
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $400.00 06/11/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740884
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.96 06/11/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740888
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.72 06/11/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740898
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740900
Principal investigator 1 Alkermes, Inc. $56.85 06/06/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614282
Principal investigator 1 Alkermes, Inc. $119.36 06/06/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616621
Principal investigator 1 Alkermes, Inc. $95.76 06/06/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618139
Principal investigator 1 Alkermes, Inc. $52.48 06/06/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618379
Principal investigator 1 Alkermes, Inc. $113.34 06/06/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621144
Principal investigator 1 Alkermes, Inc. $259.54 06/06/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623758
Principal investigator 1 Alkermes, Inc. $77.64 06/06/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626602
Principal investigator 1 Alkermes, Inc. $650.00 05/29/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618179
Principal investigator 1 Alkermes, Inc. $2,555.00 05/07/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613507
Principal investigator 1 Alkermes, Inc. $1,196.53 05/07/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614194
Principal investigator 1 Alkermes, Inc. $11,000.00 05/07/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622535
Principal investigator 1 Alkermes, Inc. $1,045.00 05/01/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613519
Principal investigator 1 Alkermes, Inc. $2,555.00 04/25/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617003
Principal investigator 1 Alkermes, Inc. $11,000.00 04/25/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620558
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,013.00 04/18/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223278486
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 04/11/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223277850
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 03/26/2025 Non-covered Recipient Entity
MERIS CLINICAL RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223277033
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,000.00 02/19/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740802
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 02/19/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740876
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.00 02/16/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740868
Principal investigator 1 Alkermes, Inc. $412.40 02/12/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613739
Principal investigator 1 Alkermes, Inc. $218.45 02/12/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614823
Principal investigator 1 Alkermes, Inc. $22.50 02/12/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615071
Principal investigator 1 Alkermes, Inc. $47.75 02/12/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617179
Principal investigator 1 Alkermes, Inc. $16.00 02/12/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617579
Principal investigator 1 Alkermes, Inc. $162.05 02/12/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622303
Principal investigator 1 Alkermes, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623666
Principal investigator 1 Alkermes, Inc. $100.30 02/12/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623676
Principal investigator 1 Alkermes, Inc. $70.40 02/12/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625195
Principal investigator 1 Alkermes, Inc. $11,000.00 02/10/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613862
Principal investigator 1 Alkermes, Inc. $2,555.00 02/10/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208619855
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $150.00 02/05/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740792
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $205.20 02/05/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740810
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $87.75 02/05/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740818
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $98.55 02/05/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740822
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4,050.00 02/05/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740850
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $60.75 02/05/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740856
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740794
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740828
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740864
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740874
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.00 01/23/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740852
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $168.75 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740812
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $540.00 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740816
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,100.00 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740820
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $75.00 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740826
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $197.10 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740830
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $183.60 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740832
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $62.10 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740834
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,800.00 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740838
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $337.50 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740842
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $400.00 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740844
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $98.55 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740848
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $205.20 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740854
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $87.75 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740870
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4,050.00 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740872
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $60.75 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740878
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,943.35 01/22/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740880
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,443.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740796
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,437.75 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740798
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $39.91 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740800
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,443.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740804
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,443.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740806
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,443.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740808
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,254.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740814
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,443.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740824
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,491.75 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740836
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $14,241.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740840
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $14,241.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740846
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,443.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740858
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,443.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740860
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,254.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740862
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,437.75 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740866
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,443.15 01/17/2025 Non-covered Recipient Entity
Meris Clinical Research, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740882
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627128
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627206
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
PHARMASEEK, LLC. dba WCG SITE NETWORK
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627278